J
John Attia
Researcher at University of Newcastle
Publications - 796
Citations - 39731
John Attia is an academic researcher from University of Newcastle. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 91, co-authored 727 publications receiving 32950 citations. Previous affiliations of John Attia include John Hunter Hospital & McMaster University.
Papers
More filters
Posted ContentDOI
Genetically informed precision drug repurposing for lung function and implications for respiratory infection
William R. Reay,Sahar I El Shair,Michael P Geaghan,Carlos Riveros,Elizabeth G. Holliday,Mark McEvoy,Stephen Hancock,Roseanne Peel,Rodney J. Scott,John Attia,Murray J. Cairns +10 more
TL;DR: An enrichment amongst glycaemic pathways of human proteins which putatively interact with virally expressed SARS-CoV2 proteins is uncovered, suggesting that antihyperglycaemic agents may have a positive effect both on lung function and Sars- CoV2 progression.
Journal ArticleDOI
The interactions between genetics and early childhood nutrition influence adult cardiometabolic risk factors
Carol A. Wang,John Attia,Stephen J. Lye,Wendy H. Oddy,Lawrence J. Beilin,Trevor A. Mori,Claire Meyerkort,Craig E. Pennell +7 more
TL;DR: In this paper, the role of genetics, early life nutrition, and the interaction between them on optimal adult health was evaluated, and it is well established that genetics, environment, and interplay between them play a crucial role in adult disease.
Book ChapterDOI
Genetic Association Studies and Next Generation Sequencing in Stroke: Methods
Jane Maguire,Elizabeth G. Holliday,Christopher Oldmeadow,John Attia,Matthew P. A. Henderson,Guillaume Paré +5 more
TL;DR: A common approach over the last 15 years has been to test for association between common genetic variants and stroke using traditional population-based designs such as case-control and cohort studies.
Journal ArticleDOI
Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
Songporn Oranratnachai,Sasivimol Rattanasiri,Ekaphop Sirachainan,Amarit Tansawet,Nilubol Raunroadroong,Gareth J. McKay,John Attia,Ammarin Thakkinstian +7 more
TL;DR: Despite significantly shorter median OS and PFS than Sorafenib, FOLFOX still extended OS by 8.22 months, which may offer clinical utility to physicians considering treatment options for aHCC in low resource settings.
Journal ArticleDOI
Patient Reported Frequency of Lupus Flare: Associations with Foundation Makeup and Sunscreen Use
TL;DR: Results highlight protective effects of wearing FM with or without SS, and suggest this reduction in flare days ultimately has potential to improve quality of life in SLE patients.